Fate Therapeutics, Inc.(FATE)- NASDAQ
  • Mon, Aug. 8, 4:11 PM
    • Fate Therapeutics (NASDAQ:FATE): Q2 EPS of -$0.29 beats by $0.03.
    • Revenue of $1.03M (+212.1% Y/Y) beats by $0.16M.
    • Shares -3.5%.
    • Press Release
    | Mon, Aug. 8, 4:11 PM
  • Mon, Jun. 20, 5:36 PM
    | Mon, Jun. 20, 5:36 PM | 17 Comments
  • Mon, Jun. 20, 12:44 PM
    | Mon, Jun. 20, 12:44 PM | 5 Comments
  • Mon, Jun. 20, 9:16 AM
    | Mon, Jun. 20, 9:16 AM | 1 Comment
  • Mon, Jun. 20, 8:52 AM
    • Thinly traded nano cap Fate Therapeutics (NASDAQ:FATE) is ahead 18% premarket on increased volume in response to its announcement that the FDA has designated lead product candidate, Phase 1/2-stage ProTmune, for Fast Track review for the reduction of incidence and severity of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT).
    • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
    • ProTmune is a programmed cellular immunotherapy that is designed for use as an allogeneic hematopoietic cell source for HCT. It is produced by modulating mobilized peripheral blood with two small molecules to enhance the biological properties and therapeutic function of immune cells. There are currently no approved therapies for the prevention of GvHD in patients undergoing allogeneic HCT.
    | Mon, Jun. 20, 8:52 AM | 10 Comments
  • Mon, May 9, 4:07 PM
    • Fate Therapeutics (NASDAQ:FATE): Q1 EPS of -$0.29 misses by $0.04.
    • Revenue of $1.3M beats by $0.5M.
    • Press Release
    | Mon, May 9, 4:07 PM
  • Fri, Apr. 15, 11:46 AM
    • Celator Pharmaceuticals (CPXX +4.6%) initiated with Buy rating and $24 (63% upside) price target by Needham.
    • Retrophin (RTRX -1.7%) initiated with Outperform rating and $25 (67%upside) price target by BMO Capital.
    • Fate Therapeutics (FATE -3.2%) initiated with Outperform rating and $4 (85% upside) price target by BMO Capital.
    • Tobira Therapeutics (TBRA +4.4%) initiated with Buy rating and $22 price target by H.C. Wainwright.
    • Wright Medical Group (WMGI +2.4%) initiated with Buy rating and $23 (21% upside) price target by Bank of America.
    • Cleveland Research rates UnitedHealth Group (UNH -0.9%) a Buy with a $155 (22% upside) price target; Anthem (ANTM -0.5%) a Buy with a $170 (20% upside) price target and Aetna (AET -0.4%) Neutral with a $120 (10% upside) price target.
    • Glaukos (GKOS +0.3%) initiated with Hold rating by Stifel.
    • Baxter International (BAX -0.3%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $58 (36% upside) from $39.
    • Baird upgrades Exactech (EXAC +0.7%) to Outperform from Neutral and raises the price target to $26 (18% upside) from $21. Stryker (SYK -0.9%) downgraded to Neutral from Outperform and raises the price target to $116 (6% upside) from $111.
    • Tenet Healthcare (THC -2.5%) upgraded to Positive from Neutral by Susquehanna.
    • Clovis Oncology (CLVS -1.5%) downgraded to Neutral from Overweight by JP Morgan. Price target lowered to $15 (7% upside) from $42.
    • AstraZeneca (AZN +0.3%) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to 3,700p (11% downside risk) from 4,400p.
    • Intercept Pharmaceuticals (ICPT +0.2%) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $80 (48% downside risk) from $100.
    | Fri, Apr. 15, 11:46 AM | 2 Comments
  • Mon, Apr. 11, 5:38 PM
    • Top gainers, as of 5.25 p.m.: SGYP +4.1%. FATE +4.0%. P +2.1%. TS +2.1%. GWB +2.0%.
    • Top losers, as of 5.25p.m.: CTRP -10.8%. JNPR -6.6%. AA -4.5%. SRC -2.7%.
    | Mon, Apr. 11, 5:38 PM | 5 Comments
  • Thu, Mar. 3, 4:05 PM
    • Fate Therapeutics (NASDAQ:FATE): Q4 EPS of -$0.26 beats by $0.01.
    • Revenue of $1.1M beats by $0.52M.
    | Thu, Mar. 3, 4:05 PM | 1 Comment
  • Wed, Feb. 3, 12:49 PM
    | Wed, Feb. 3, 12:49 PM | 1 Comment
  • Wed, Jan. 27, 9:22 AM
    | Wed, Jan. 27, 9:22 AM | 3 Comments
  • Wed, Jan. 27, 8:35 AM
    • Thinly traded nano cap Fate Therapeutics (NASDAQ:FATE) is up 17% premarket on increased volume in response to its announcement that the FDA has approved its Investigational New Drug (IND) application for lead product candidate ProTmune. The company intends to initiate a Phase 1/2 clinical study in adults with malignant blood cancers undergoing mobilized peripheral blood (mPB) hematopoietic cell transplantation (HCT) by mid-year. The trial will assess ProTmune's ability to prevent acute graft-versus-host disease (GvHD) and cytomegalovirus (CMV) infection in patients undergoing HCT.
    • The trial first phase will enroll 10 patients to assess safety and tolerability. Following a successful review by the independent data monitoring committee, the second phase will enroll 60 subjects who will be randomized to receive either ProTmune or unmanipulated mPB cells.
    • According to the Center for International Blood and Marrow Transplant Research, about 30K HCT procedures are performed each year worldwide, 65% of which use mPB as the donor cell source. 35 - 50% of HCT patients develop acute GvHD and 70 - 80% experience at least one severe infection.
    • ProTmune is a programmed cellular immunotherapy that is designed for use as an allogeneic hematopoietic cell source for HCT. It is produced by modulating mobilized peripheral blood with two small molecules to enhance the biological properties and therapeutic function of immune cells. There are currently no approved therapies for the prevention of GvHD in patients undergoing allogeneic HCT.
    | Wed, Jan. 27, 8:35 AM | 1 Comment
  • Tue, Jan. 26, 5:37 PM
    • Top gainers, as of 5.25 p.m.: FATE +19.7%. ETH +6.8%. HA +6.0%. STAG +5.2%. INO +5.0%.
    • Top losers, as of 5.25p.m.: ARGS -14.4%. CIE -13.2%. LCI -10.9%. X -9.9%. DYN -8.0%.
    | Tue, Jan. 26, 5:37 PM | 12 Comments
  • Nov. 3, 2015, 4:06 PM
    • Fate Therapeutics (NASDAQ:FATE): Q3 EPS of -$0.24 beats by $0.06.
    • Revenue of $1M beats by $0.57M.
    | Nov. 3, 2015, 4:06 PM
  • Oct. 28, 2015, 3:24 PM
    • Thinly traded micro cap Fate Therapeutics (FATE +23.8%) is up a 3x surge in volume, albeit on turnover of only 264K shares, in response to its announcement that the USPTO has awarded U.S. Patent No. 9,169,490 covering cell compositions expressing enough octamer-binding transcription factor 4 (Oct 4) to enable pluripotency. The patent is owned by the Whitehead Institute for Biomedical Research and licensed exclusively to Fate for all therapeutic purposes.
    • Fate's cell-based product pipeline of off-the-shelf NK- and T cell-based therapies is derived from induced pluripotent cells.
    | Oct. 28, 2015, 3:24 PM
  • Oct. 28, 2015, 12:49 PM
    | Oct. 28, 2015, 12:49 PM
Company Description
Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the... More
Sector: Healthcare
Industry: Biotechnology
Country: United States